AM-9022

AM-9022 Suppliers list
Company Name: Nantong QuanYi Biotechnology Co., Ltd  
Tel: 0513-66337626 18051384581
Email: sales@chemhifuture.com
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
AM-9022 Basic information
Product Name:AM-9022
Synonyms:AM-9022;Benzamide, 2-(6-azaspiro[2.5]oct-6-yl)-N-[2-(4,4-difluoro-1-piperidinyl)-6-methyl-4-pyrimidinyl]-4-[[[(1R)-2-hydroxy-1-methylethyl]sulfonyl]amino]-
CAS:2446872-46-2
MF:C27H36F2N6O4S
MW:578.68
EINECS:
Product Categories:
Mol File:2446872-46-2.mol
AM-9022 Structure
AM-9022 Chemical Properties
density 1.425±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)
pka7.199±0.10(predicted)
form Solid
color White to off-white
Safety Information
MSDS Information
AM-9022 Usage And Synthesis
UsesAM-9022 is an orally active, potent, selective KIF18A inhibitor that can be used for research on cancer[1].
in vivo

AM-9022 (30-100 mg/kg; p.o.; daily for 18 or 21 days) has significant anti-cancer effects in breast and ovarian tumor models at well-tolerated doses[1].

Animal Model:Female athymic nude mice were injected with OVCAR-3 cells (5 x 106) subcutaneously in the right flank. Femal CB.17 SCID mice were injected with JIMT-1 cells (1.0×107) subcutaneously in the right flank) (6-8 weeks)[1]
Dosage:30 mg/kg (OVCAR-3 CDX tumors mice); 30, 100 mg/kg (JIMT-1 tumors mice)
Administration:Oral gavage (p.o.); daily for 18 days or 21 days
Result:Increased pH3 mitotic marker levels in OVCAR-3 tumors by 3.4-fold, with higher compound exposure in tumors relative to plasma in OVCAR-3 CDX tumors mice.
Inhibited tumor growth, with evidence of tumor regression (TR) (95% TR, six of ten tumor-free mice) and no body weight loss in OVCAR-3 CDX tumors mice.
Inhibited tumor growth with evidence of TR (16% and 94% TR, respectively) at well-tolerated doses in JIMT-1 tumors mice.
The plasma AUC value at 30mg/kg was 3.7-fold higher in the JIMT-1 model relative to the OVCAR-3 model.
References[1] Payton M, et al. Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers. Nat Cancer. 2023 Dec 27. DOI:10.1038/s43018-023-00699-5
AM-9022 Preparation Products And Raw materials
Tag:AM-9022(2446872-46-2) Related Product Information
Benzamide, 2-(6-azaspiro[2.5]oct-6-yl)-N-[2-(4,4-difluoro-1-piperidinyl)-4-pyridinyl]-4-[[(2-hydroxyethyl)sulfonyl]amino]- AM-9022 Benzamide, 2-(6-azaspiro[2.5]oct-6-yl)-N-[2-(4,4-difluoro-1-piperidinyl)-6-methyl-4-pyrimidinyl]-4-[[[(1S)-2-hydroxy-1-methylethyl]sulfonyl]amino]- Sovilnesib Ispinesib MonoMethyl auristatin E